Several recent developments flying under the radar right now:
The patent appeal that is unfavorable to GSK presents three major strategic plays to acquire Amarin (NASDAQ:AMRN):
1. GSK main player - in order to defend against Lovaza revenue loss from potential future generics
2. AZN back in as a suitor - in order to maintain a player in the Omega-3 space --the Lovaza generic ruling cancels out Omthera completely
3. Teva now makes more sense - in order to lock up the Omega-3 drug class and price protect against other generic plays
Also, AMRN has named Lipator as the stain agent to be patented with Vascepa. That means PFE prime suitor as well.
I will reiterate my stand on NCE success, Anchor approval in December and a $28-32 short term (within 12-mo) price target.